日前，北京市发展改革委联合有关部门针对昌平等五区发布"一区一策"平原新城高质量发展实施方案。昌平 不仅是培育新质生产力的前沿阵地，更是着力打造的科技创新策源地、产业升级新高地。创新与创业的火花 在这里竞相迸发，平均每天80多家新企业在此诞生，注入发展动能。这里正在科技创新、产业向新、城市焕 新的三重奏中，向世界展示一座现代化创新之城的崭新面貌。 科技创新赋能 夜幕降临，位于昌平区的北京未来科学城实验楼灯火通明。走进北京齐禾生科生物科技有限公司实验室，研 究人员正操作移液枪，将透明液体滴入培养皿。"每天这里都可能诞生改变世界的科技成果。"齐禾生科CEO 张蓓说。 北京北部，群山环抱，曾因温泉、草莓和十三陵闻名的昌平，如今已是科技创新的热土。2024年，昌平地区 生产总值增长6.6%，成为北京经济增速最快的区域；固定资产投资增长16.4%，创历史新高；居民人均可支 配收入增长5.6%，增速全市第一。 "昌平区汇集41所高校、69个国家级和省部级重点实验室、210个工程技术中心，全国重点实验室数量占全市 三分之一以上，研发经费投入强度保持在6.5%的较高水平。"北京市昌平区委副书记、区长刘晓东说，近年 来，昌平立足 ...

領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 內幕消息 業務更新 本公告乃由領航醫藥及生物科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部之內幕消息條文（定義見上市 規則）而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 此計劃符合全球數碼轉型趨勢，並提供機會令本集團的收益來源更多元化，同 時提升在新興行業的競爭地位。 資金及管理 為支持該計劃，本公司可能透過不同方式籌集資金，包括配售，以及向股東或 財務機構借貸。本公司亦可能擴大董事會及高級管理層團隊以納入合資格人 士以確保新項目的成功。 前景及管理層觀點 本公司董事（「董事」）會（「董事會」）欣然提供本集團業務計劃的最 ...

Core Viewpoint - The company focuses on food safety rapid testing and animal diagnostics, aiming to expand its market presence both domestically and internationally through innovative products and strategic partnerships [5][10][19]. Company Overview - The company specializes in food safety rapid testing and is expanding into animal diagnostics, providing comprehensive testing solutions across various stages of the food supply chain [5][10]. - The main products include rapid test reagents, testing instruments, and related services, ensuring food safety from production to retail [6][8]. Business Segments Food Safety Rapid Testing - The company offers a range of rapid test products, including immunochromatographic test strips and ELISA kits, applicable to various food categories such as dairy, meat, and vegetables [6][7]. - The company has developed a high-throughput multi-residue testing card for pesticide residues, capable of detecting 16 types of pesticides simultaneously within 9 minutes [8][22]. Animal Diagnostics - The animal diagnostics segment is managed by a wholly-owned subsidiary, focusing on rapid testing for livestock and companion animals, including pregnancy tests and pathogen detection [10][24]. - The company aims to leverage its existing customer base in food safety to enhance sales in animal diagnostics, particularly in markets with significant livestock populations [24]. Market Strategy - The company is deepening its international strategy, targeting untapped markets in dairy product testing and other areas, with a focus on obtaining local certifications and building partnerships [19][20]. - The global market for mycotoxin testing kits is projected to reach $825.7 million by 2028, indicating significant growth potential for the company's products in this area [19]. Regulatory Environment - Increasing domestic regulations on food safety are driving demand for testing services, as companies seek to comply with stricter standards [25]. - The company is positioned to benefit from heightened consumer awareness regarding food safety, leading to increased testing requirements from food producers and retailers [25]. Technological Innovation - The company has developed an automated digital testing platform that enhances testing efficiency and reduces costs for clients, integrating data management and real-time monitoring [26]. - A new chemiluminescence technology platform allows for multi-parameter testing in a single device, streamlining the testing process and improving accuracy [27]. Financial Performance - The company has maintained a stable financial position, with no need for restating previous financial data, indicating consistent operational performance [30]. - The company has received various certifications, reflecting its commitment to quality and innovation in the testing industry [29].

金十数据4月24日讯，睿昂基因发布一季报，营业收入为5473.80万元，同比下降14.72%；归属于上市公 司股东的净利润为335.50万元，同比增长529.26%。净利润增长主要系子公司长春技特收到流式细胞相 关研究项目政府补助尾款180万；收回前期单项计提的一笔应收坏账247.63万元。 睿昂基因：一季度净利润同比增长529.26% ...

| 半导体ETF - ... | 203.47 | +4.56 (+2.29%) | 67.82万股 | 24.05亿 | | --- | --- | --- | --- | --- | | us SMH | | | | | | 网络股指数E ... | 222.01 | +3.47 (+1.59%) | 8124服 | 147.41亿 | | us FDN | | | | | | 科技行业ET ... | 200.92 | +2.88 (+1.45%) | 31.25万股 | 639.04亿 | | us XLK | | | | | | 黄金ETF-SP ... | 305.87 | +2.21 (+0.73%) | 163.93万股 | 827.36亿 | | us GLD | | | | | | 能源业ETF - ... | 81.77 | +0.53 (+0.65%) | 77.68万股 | 204.77亿 | | us XLE | | | | | | 全球科技股 ... | 73.50 | +0.43 (+0.59%) | 7011股 | 10.29亿 | | us IXN | | | | | | ...

贝瑞基因（000710）公告，2024年营业收入10.78亿元，同比下降6.36%。归属于上市公司股东的净亏损 1.92亿元，去年同期净亏损4.27亿元。基本每股收益-0.5443元/股。公司计划不派发现金红利，不送红 股，不以公积金转增股本。 ...

Investment Rating - The report assigns a "Buy" rating to the company 康方生物 (9926 HK) with a target price of HKD 115.00, indicating a potential upside of 30.1% from the current price of HKD 88.40 [1][7][13]. Core Insights - The success of the second head-to-head Phase III trial for the drug 依沃西 (Ivosidenib) has validated its competitive advantage in the lung cancer treatment market compared to PD-(L)1 monotherapy. The trial achieved significant benefits in progression-free survival (PFS) [7]. - The company has received approval for its first autoimmune product, 依若奇单抗 (Ilumya), which is expected to generate peak sales of approximately RMB 1 billion due to its advantages over competitors in treating moderate to severe plaque psoriasis [7]. - The revenue forecasts for 2025-2027 have been adjusted upwards by 0-6%, with peak sales estimates for 依沃西 in mainland China and overseas raised to RMB 6.1 billion and USD 5.7 billion, respectively [7]. Financial Overview - Revenue projections for 康方生物 are as follows: RMB 4,095 million in 2025, RMB 6,091 million in 2026, and RMB 8,680 million in 2027, reflecting growth rates of 92.8%, 48.8%, and 42.5% respectively [6][15]. - The net profit is expected to recover from a loss of RMB 446 million in 2024 to RMB 629 million in 2025, and further increase to RMB 1,982 million in 2026 and RMB 3,557 million in 2027 [6][15]. - The company’s market capitalization is approximately HKD 79.17 billion, with a year-to-date stock price increase of 45.63% [4][6]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to be 112.8x in 2025, decreasing to 35.8x in 2026 and further to 19.9x in 2027, indicating improving profitability [6][8]. - The book value per share is expected to rise from RMB 5.58 in 2023 to RMB 14.58 in 2027, with a corresponding decrease in the price-to-book (P/B) ratio from 14.94x to 5.72x [6][8].

【SynBioCon】 获 悉， 近日，百开盛生物宣布 瑞鲍迪苷M （Rebaudioside M，RebM）产品正 式通过美国GRAS（一般公认安全）认证， 将为全球食品工业减糖提供"中国方案"。 瑞鲍迪苷M（RebM）是一种天然高倍甜味剂，甜度通常是蔗糖的 200-300 倍。作为一种甜叶菊中的稀有单体，相 比其他甜菊糖苷（如瑞鲍迪苷A），其苦味和后苦味更弱，口感更接近蔗糖，在食品、饮料、膳食补充剂和动物营 养等多个领域展现出广泛的市场应用潜力。 百开盛生物基于独有的酶与生物催化技术平台，实现瑞鲍迪苷生产关键酶的发掘及 定向进化 ，生产 效率相对传统植物合成提高近千倍。 结合自有过程工程技术平台，使所生产的瑞鲍迪苷M产品纯度 （RM≥95%）媲美植物提取，满足高端应用场景需求。 "GRAS"是"Generally Recognized As Safe（一般公认安全）"的缩写, 是美国食品成分的一种重要分类。随着食品技术 尤其是合成生物学技术的不断进步及食品贸易全球化的发展，GRAS认证因其高度的权威性和国际认可度，已成为 众多企业进军国际市场的关键通行证。 参 考 信息 ： 本文素材来自百开盛生物 ，本平 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)3诺唯赞-558.56-558.562.56101.06亿行业平均 46.4449.384.75102.60亿行业中值30.3929.672.3746.63亿1天益医疗-2730.40-2730.401.7120.31亿2硕世生 物-1866.14-1866.141.1738.55亿4博晖创新-352.86-217.263.8954.16亿5康泰医学-269.6131.632.7552.44亿6 华大基因-201.20220.082.08204.46亿7奥精医疗-110.28-110.281.4119.98亿8睿昂基因-81.33-81.331.2611.76 亿9热景生物-62.30-62.303.43111.65亿10华大智造-53.01-53.013.98317.59亿11中红医疗-49.41- 33.620.7843.99亿 来源：金融界 南京诺唯赞生物科技股份有限公司的主营业务是围绕酶、抗原、抗体等功能性蛋白及高分子有机材料进 行技术研发和产品开发。公司的主要产品是生物试剂、诊断试剂、仪器设备、技术服务、耗材等材料。 最新一期业绩显示，2024年 ...

记者获悉，本届消博会共有来自71个国家和地区的1700余家消费企业、4100余个消费品牌参展，英国、瑞士、加拿大等近20个国家和地区组团参展，65家世界500强和龙头企业 参展，数量均超过上届。主会场共设置了八大展馆，聚焦科技消费、健康消费、绿色消费、时尚消费、低空经济等消费热点，展示国内外"新、奇、特、优"精品和新品。 以下文章来源于e公司 ，作者唐强 曹晨 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价 的主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 4月13日，第五届中国国际消费品博览会（简称"消博会"）、"购在中国"系列活动在海南海口正式启动，本届消博会为期6天（4月13日～18日）。 尽管"椰城"海口已经下起了小雨，但这并没有阻挡住参会观众的热情。4月13日上午，证券时报记者来到本届消博会的活动现场发现，海南国际会议展览中心外早已人头攒动， 国内外参展商们热情高涨，等待入场的人们已经排起了长队。 深化经贸合作实现互利共赢 作为全球消费精品展示交易平台，消博 ...